Ipca Laboratories Ltd

IPCALAB06 Dec 2024
Pharmaceuticals
+42.45 (+2.84%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in Ipca Laboratories Ltd
Ipca Laboratories Ltd
Pharmaceuticals
IPCALAB06 Dec 2024
+42.45 (+2.84%)
1D
1M
6M
1Y
5Y
All

Ipca Laboratories Ltd - Share Price & Details

Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
36.52%
Upper Circuit
Lower Circuit
P/E TTM
55.91
P/B Ratio
5.79
Traded Value(Cr)
0.00
EPS TTM
27.5
Book value
Dividend
0.26%

Invest in Ipca Laboratories Ltd at ZERO Brokerage for 30 days

Price Performance

-0.39 %
1 Wk
-2.89 %
1 M
8.03 %
3 M
36.52 %
1 Y
37.35 %
YTD

Traded Volume Movement

Technical Details

Support 3
1470
Support 2
1485
Support 1
1512
Pivot Point :
1527
Resistance 1
1554
Resistance 2
1569
Resistance 3
1596

Reports

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
Ipca Laboratories Ltd
₹1,537.45(+42.45/2.84%)
1,537.45+42.4539,005.7636.5255.915.79
58.37+0.38447.3143.0650.769.93
Astrazeneca Pharma India Ltd
₹6,632.55(+2.00/0.03%)
6,632.55+2.0016,581.3837.91128.8124.41
Abbott India Ltd
₹29,053.50(+29.75/0.10%)
29,053.50+29.7561,738.6925.9148.0617.53
Amrutanjan Health Care Ltd
₹722.80(-15.20/-2.06%)
722.80-15.202,089.6621.2343.977.02
Bliss GVS Pharma Ltd
₹157.90(-2.90/-1.80%)
157.90-2.901,663.1918.2820.591.62

About Ipca Laboratories Ltd

Ipca Laboratories Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 39005.76 crores. It has reported a sales of Rs. 1810.94 crores and a net profit of Rs. 244.12 crores for the quarter ended December 2018. The company management includes Premchand Godha, Premchand Godha,A K Jain,Pranay Godha,Prashant Godha,Kamal Kishore Seth,Narendra Mairpady,Harish P Kamath,Swati Patankar,Vivek Shiralkar (Ipca Laboratories Ltd) among others.
Chairman
Premchand Godha
Registered office
48 Kandivli Industrial Estate,Kandivli (West),Mumbai,Maharashtra,400067
FAX :91-22-28686613
Background
Incorporation Year1949
Face Value₹1
Market Lot1

Latest News

Can Nifty reclaim 24,700, Bank Nifty hold above 53,500 amid consolidation

Both Nifty 50 and Bank Nifty recorded minor profit booking amid volatility on December 6, after rising for five consecutive days. This resulted in small bearish candlestick patterns on the daily charts. The momentum remains strong, but considering the recent healthy rally, the Nifty 50 may see some range-bound trade, with immediate support at 24,500, followed by 24,350 as the key support level.
08 Dec 2024 | 06:12 PM

M-cap of 6 of top 10 most valued firms jumps Rs 2 lakh crore

The market valuation of India's top 10 firms surged Rs 2,03,116.81 crore last week, led by Tata Consultancy Services and HDFC Bank, as the BSE benchmark jumped 1,906.33 points and NSE Nifty climbed 546.7 points. The biggest gainers included Reliance Industries, Infosys, State Bank of India, and ICICI Bank, while Bharti Airtel, LIC, ITC, and Hindustan Unilever were the laggards.
08 Dec 2024 | 12:02 PM

These 3 stocks will likely head north in the coming week- Sudeep Shah

Sensex has found support near its 200-day EMA level and witnessed a sharp rally, surging over 6% in just 12 sessions. Along with this, it has surged above its short and long-term MAs. Sudeep Shah, Head, Technical & Derivatives Research (Equity), at SBI Securities, believes that 💰BSE, 💰PB Fintech, and 💰Paytm stocks are likely to continue their northward trek over the next few trading sessions.
08 Dec 2024 | 04:56 PM

M-cap of 6 of top 10 most valued firms jumps Rs 2 lakh crore

The market valuation of India's top 10 firms surged Rs 2,03,116.81 crore last week, led by Tata Consultancy Services and HDFC Bank, as the BSE benchmark jumped 1,906.33 points and NSE Nifty climbed 546.7 points. The biggest gainers included Reliance Industries, Infosys, State Bank of India, and ICICI Bank, while Bharti Airtel, LIC, ITC, and Hindustan Unilever were the laggards.
08 Dec 2024 | 12:02 PM

Stocks to buy or sell: Dharmesh Shah of ICICI Securities recommends!

For Nifty, the weekly price action formed a strong bull candle carrying higher high-low formation, indicating acceleration of up move. Stocks recommended to buy tomorrow by Dharmesh Shah-
📌Buy State Bank of India (SBI) in the range of 830-863 for the target of 950 with a stop loss of 787.
📌Buy Nalco in the range of 242-248 for the target of 266 with a stop loss of 235.
08 Dec 2024 | 06:34 PM

How to buy Ipca Laboratories Ltd shares on nse?

To buy Ipca Laboratories Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Ipca Laboratories Ltd share price today?

The Ipca Laboratories Ltd shares price on nse is Rs.1537.45 today.

What is the market cap of Ipca Laboratories Ltd shares on BSE ?

The company has a market capitalization of Rs.39005.76Cr

What is the PE & PB ratio of Ipca Laboratories Ltd shares ?

PE is 55.91 and PB is 5.79

What is the 52 Week High and Low of Ipca Laboratories Ltd shares?

Ipca Laboratories Ltd stock price high: Rs.1708.7 Ipca Laboratories Ltd stock price low: Rs.1042

Is Ipca Labs a government-run institution?

No, IPCA Laboratories is not a government-run organization. It is a privately-owned pharmaceutical company based in India. IPCA Laboratories was founded in 1949 and has since grown to become one of the leading pharmaceutical companies in India.

Who is Ipca Labs’ owner?

IPCA Laboratories is a publicly-traded company and its ownership is spread among its shareholders. The Promoter of IPCA Labs is Mr. Premchand Godha and his family.

How well is Ipca Labs doing?

IPCA Laboratories operates in the pharmaceutical industry and has a diverse product portfolio that includes medicines for various therapeutic segments, including antimalarials, anti-bacterial, pain management, and cardiovascular drugs.

Ipca Labs’ consolidated revenue has gone from Rs. 3773.18 crores in March 2019 to  Rs. 5,829.79 crores on 31 March 2022. The net profit has gone from Rs. 443.03 crores to Rs. 910.95 crores in the same period.

Ipca Labs stock has given a positive return of 10.05% over the past three years and a negative return of -18.57% over the past one year.

 

What are the latest results of Ipca Labs?

The last fiscal result of Ipca Labs was declared in March 2022 and they reported a consolidated revenue of INR 5,829.79 crore and net profit of Rs. 910.95 crores.

What are the potential catalysts that positively impact the stock price of Ipca lab?

Some potential catalysts that may positively affect IPCA Laboratories' stock price could include:

  • Strong financial results
  • Expansion in new markets
  • Launch of new products
  • Regulatory approvals
  • Industry trends
Click here to see your activities